Skip to main content
. Author manuscript; available in PMC: 2009 Jul 7.
Published in final edited form as: Update Cancer Ther. 2007 Jun 1;2(2):61–65. doi: 10.1016/j.uct.2007.06.001

Table 1.

Phase 1 studies of CD40 agonist therapy in cancer patients

Drug Formulation CD40 signaling Patient population Clinical trial findings References
Recombinant CD40L Recombinant human trimer Agonist Solid tumors or NHL
N=32

  • Increased AST/ALT

  • Injection site reactions

  • 2 PR

 Vonderheide et al. J Clin Oncol, 2001
CP-870,893 Fully human IgG2 mAb Agonist Solid tumors
N=29

  • CRS

  • 4 PR

 Vonderheide et al. J Clin Oncol, 2007
SGN-40 Humanized IgG1 mAb Weak agonist NHL
N=35

  • CRS

  • 3 PR, 2 CR

 Advani et al. Blood 2006
Multiple myeloma
N=32 (ongoing)

  • CRS

  • No clinical responses

 Husein et al. Blood 2006

NHL, Non-Hodgkins lymphoma; PR, partial response; CR, complete response; CRS, cytokine release syndrome